On December 8, 2020, positive preliminary results of the phase I study (NCT04278768) of CA-4948 monotherapy for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), were released.¹ Results of this study were also presented as a poster at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition.²

CA-4948 is a first-in-class inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 plays an essential role in the toll-like receptor (TLR) and interleukin-1 receptor signaling pathways, which are frequently dysregulated in non-Hodgkin lymphoma, AML, and MDS. The long form of IRAK4 (IRAK4-L) has also demonstrated oncogenic activity and is preferentially expressed in ~50% of patients with AML and MDS.^1,2

CA-4948^1-3

First-in-class suppressor of the TLR pathway³
Orally administered, novel small molecule inhibitor of IRAK4 kinase¹
Demonstrates inhibition of FLT3 in in vitro and in vivo models²

NCT04278768⁴

A phase I, single arm, dose escalation study of CA-4948 in adult patients (≥ 18 years) with AML or high-risk MDS
Primary outcomes: Maximum tolerated dose, recommended phase II dose
Secondary outcomes: Pharmacodynamics and pharmacokinetics
Exploratory outcomes: Pharmacodynamics on selected biomarkers in peripheral blood and bone marrow
Three study cohorts: 200 mg twice daily; 300 mg twice daily; 400 mg twice daily; in 28-day cycles

Results^1,2

7 patients have been enrolled in the first two dose cohorts (n = 3, AML patients; n = 4, MDS patients)
Patients had a median of three prior lines of therapy (range 1–4)
6/7 patients remain enrolled in the study
No dose-limiting toxicities were reported
All evaluable patients (6/7) had marrow blast reductions
Marrow complete responses were seen in two patients:
- blast counts decreased from 23% to 1% in one patient and from 11% to 2% in the other patient

Based on these results, enrollment has begun in the 400 mg dose group. CA-4948 is also being studied in a phase I trial (NCT03328078) for non-Hodgkin lymphoma, which was presented as an oral abstract at the 62nd ASH Annual Meeting & Exposition.⁵ If further clinical trials demonstrate positive results, CA-4948 could provide a new treatment option for the R/R setting, where there is currently an unmet clinical need.

[[references1]]

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

ASH 2020

ASH 2020

All Events